Schrodinger Inc stock (US80655G1067): Q1 loss and revenue miss weigh on shares

Schrodinger Inc reported a wider first?quarter 2026 loss and missed revenue estimates, sending its Nasdaq?listed stock lower on the day.

Schrodinger Inc shares traded at about 13.28 USD on May 7, 2026, on Nasdaq, according to MarketBeat as of 05/07/2026. The move comes after the company reported first?quarter 2026 financial results that showed a net loss and revenue below analyst expectations, reinforcing concerns about the path to profitability for the computational?drug?discovery platform provider.

As of: 08.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Schrödinger, Inc.
• Sector/industry: Life sciences software and drug discovery
• Headquarters/country: New York, United States
• Core markets: Global pharmaceutical and biotech companies
• Key revenue drivers: Software subscriptions, research?services collaborations, and milestone payments
• Home exchange/listing venue: Nasdaq (ticker: SDGR)
• Trading currency: USD

Schrodinger Inc: core business model

Schrodinger Inc operates a computational?drug?discovery platform that combines physics?based simulations with machine learning to help pharmaceutical and biotechnology companies design and optimize new drug candidates. The company licenses its software to large pharma firms and also enters into research?services collaborations where it applies its platform to specific therapeutic targets in exchange for upfront fees, milestones, and royalties.

By integrating molecular modeling, quantum mechanics, and artificial intelligence, Schrodinger aims to shorten discovery timelines and reduce the cost of bringing new medicines to market. Its customers include major global drugmakers and mid?sized biotechs, giving the company exposure to both established pipelines and early?stage innovation, according to Schrodinger as of 05/08/2026.

Main revenue and product drivers for Schrodinger Inc

Schrodinger’s revenue is split between software?subscription fees and research?services contracts. Software revenue comes from annual or multi?year licenses of its computational?chemistry and drug?discovery suites, while research?services revenue is generated through collaborative projects that can include discovery?stage work, lead optimization, and preclinical support.

In the first quarter of 2026, the company reported a net loss of about 60 million USD, or 0.81 USD per share, compared with a net loss of 59.8 million USD, or 0.82 USD per share, in the prior?year quarter, according to Schrodinger investor relations as of 05/07/2026. Revenue for the period missed analyst estimates, underscoring the challenge of converting its technology leadership into consistent top?line growth and profitability.

Why Schrodinger Inc matters for US investors

For US investors, Schrodinger Inc offers exposure to the intersection of life?sciences software, artificial intelligence, and drug discovery, a segment that is increasingly central to large?cap pharma R&D. The company’s Nasdaq listing provides liquidity and visibility, while its client base includes several US?based biopharma firms, linking its performance to domestic innovation cycles and regulatory trends.

At the same time, the stock’s volatility reflects the high?risk, high?reward nature of pre?profitability growth names in the life?sciences software space. US retail investors often weigh Schrodinger against other computational?biology and AI?driven healthcare plays, making it a barometer for sentiment toward tech?enabled drug discovery, according to MarketBeat as of 05/07/2026.

Conclusion

Schrodinger Inc’s first?quarter 2026 results highlight the tension between technological promise and near?term financial performance. The wider net loss and revenue miss have weighed on the stock, reflecting investor sensitivity to execution risks in a capital?intensive, research?driven business model.

On the other hand, the company’s platform remains embedded in the discovery workflows of major pharma partners, which could support future revenue if collaborations convert into milestones and royalties. For US investors, Schrodinger Inc represents a speculative bet on the long?term role of computational methods in drug discovery, rather than a near?term income or value play.

Given the lack of profitability and the stock’s volatility, investors may want to consider position sizing and diversification carefully, especially in a rising?rate environment where growth?oriented names often face higher discount?rate pressure, according to MarketBeat as of 05/07/2026.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.